Is Regeneron Pharmaceuticals (REGN) One of the Best Gene-Editing Stocks to Buy According to Hedge Funds?
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best gene-editing stocks to buy according to hedge funds.
Regeneron Pharmaceuticals Inc. (REGN)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Two Sigma Advisors John Overdeck And David Siegel | 926,200 | $520,774,474 | -2% | 1.04% |
| 2. | D E Shaw D. E. Shaw | 861,593 | $484,447,896 | +11% | 0.27% |
| 3. | AQR Capital Management Cliff Asness | 721,354 | $405,595,821 | +529% | 0.26% |
| 4. | 400,000 | $224,908,000 | +793% | 2.15% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 386,884 | $217,533,266 | +62% | 0.22% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $487.01 | 2,557 | $1,245,286.62 | 23,880,537 | 2017-08-25 | Filing | |
| $485.99 | 2,681 | $1,302,949.65 | 23,877,980 | 2017-08-25 | Filing | |
| $485.28 | 5,723 | $2,777,256.30 | 23,875,299 | 2017-08-25 | Filing | |
| $484.21 | 2,000 | $968,420.00 | 23,869,576 | 2017-08-25 | Filing | |
| $482.87 | 4,485 | $2,165,687.20 | 23,867,576 | 2017-08-25 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $651.43 | 431 | $280,766.33 | 4,233 | 2025-11-07 | Filing | |
| $657.29 | 388 | $255,028.52 | 2,352 | 2025-10-29 | Filing | |
| $656.50 | 712 | $467,428.00 | 2,740 | 2025-10-29 | Filing | |
| $655.10 | 100 | $65,510.00 | 3,452 | 2025-10-29 | Filing | |
| $654.42 | 1,915 | $1,253,214.30 | 3,552 | 2025-10-29 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,048,269 | $5,087,570,211 | 0.08% | |
| 2. | 8,837,174 | $4,968,878,140 | 0.09% | |
| 3. | 4,691,223 | $2,637,733,956 | 0.09% | |
| 4. | 4,550,845 | $2,558,803,618 | 1.38% | |
| 5. | 4,072,326 | $2,289,760,415 | 0.14% |
News See All
9 Best Gene-Editing Stocks to Buy According to Hedge Funds
Genetic manipulation – or gene editing – is a concept that describes altering the genetic material (DNA) of an organism.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q3 2025 Earnings Call Transcript October 28, 2025Regeneron Pharmaceuticals, Inc. beats earnings expectations.
Long Leaf Partners Fund’s Comment on Regeneron (REGN)
Longleaf Partners, managed by Southeastern Asset Management, released its “Partners Fund” third-quarter 2025 investor letter. The letter can be downloaded here.
12 Most Undervalued Long-Term Stocks to Buy Right Now
On October 23, Gene Goldman, CIO at Cetera, joined CNBC television to discuss the market valuations and the sectors he thinks are undervalued.
Regeneron Pharmaceuticals, Inc. (REGN) Prepares for $83M Charge
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top stocks to buy in Michael Burry’s stock portfolio.
Michael Burry Stock Portfolio: 6 Stocks to Buy
Michael Burry needs no introduction on Wall Street.
Regeneron (REGN) Highlights Benefits of Semaglutide and Trevogrumab in Obesity Management
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ranks among the best biotech stocks to buy. On September 17, Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) Draws Attention With Rare Disease Breakthrough
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is among the most promising biotech stocks to buy according to hedge funds.
Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials
On September 17, 2025, Regeneron Pharmaceuticals Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
